AI to aid fertility – Apricity Fertility Predictor® launches

24 June 2019 – London: Revolutionary UK health tech brand, Apricity, has announced it has designed algorithms to better understand the key success factors in fertility treatment, based on patient’s type of infertility and age. The Apricity Fertility Predictor® is the first AI tool available to women and couples who struggle to conceive, using new algorithms to help people understand different fertility treatments that may be beneficial to them, and then evaluating their chances of success with each recommended type of treatment.

Apricity is the first UK virtual fertility care provider that combines medical excellence with human care and new technologies to help people conceive. Connecting people with the best clinics in the UK, all with added personalised support and care. The company conducts ambitious AI projects within the field of fertility, designing AI-driven algorithms to help patients better understand their chances of success and empower them with truly customised and supported care.

 The Apricity Fertility Predictor® is available on the Apricity website www.apricity.life and has been developed by a team of data engineers, data scientists and developers. Based on 400,000* UK cycles and with a methodology which is based on machine learning algorithms, the Apricity Fertility Predictor® is innovation that paves the way for the future of fertility.

Apricity is deeply committed to artificial intelligence in the field of fertility, with topics that include automated embryo selection, thanks to deep learning algorithms or hormonal treatment optimisation. The Apricity Fertility Predictor® will be unveiled at ESHRE at the end of June, where Apricity’s scientific committee, composed of world-renowned fertility specialists, epidemiologists and embryologists will gather once more to discuss the significant and positive impact of AI in the world of fertility.

Through exploration within the Apricity Fertility Predictor®, patients might learn of treatment options they did not originally know were available to them. For women aged 45 and over, for example, using an egg donor increases their chance of having a baby by 8 times. The tool is the first of its kind that allows women and men to explore options from the outset and offers full transparency on what treatments may be required.

Apricity also leads the fertility domain in the ambitious Healthchain project, supported by BPI France as part of a consortium coordinated by Owkin, and including the Substra association, Apricity, the APHP (Assistance Publique des Hôpitaux de Paris), the University Hospital Centre of Nantes, the Léon Bérard Centre, the French National Centre for Scientific Research, the École Polytechnique, the Institut Curie and the University of Paris Descartes.

Working with a strong team and with leading fertility centres across the globe, it has gathered anonymised data on patient cycles in order to take fertility treatment into a new era. Through sophisticated AI, federated learning and blockchain technology, Apricity wants to allow development of machine learning models on large medical datasets in fertility, still guaranteeing the privacy and security for all data owners.

Caroline Noublanche, CEO and Co-Founder, Apricity, says: “at Apricity we have an incredible team of data engineers, data scientists and developers, who have used publicly available anonymised data from the HFEA. The data has enabled us to create the Apricity Fertility Predictor®, which we are excited to unveil at ESHRE. Our aim is to create transparency in the fertility sector and give patients more control and options. It is a first step in our ambitious AI strategy, and we are looking forward to open the cooperation with more leaders in the fertility world to shape together the future of fertility.”

Apricity’s dedicated AI team is committed to working and partnering with the best fertility centres in the world and giving them the support they need for robust evaluation, aiming to maximise the chances of conceiving for fertility patients.